Prevalence of Neuropathic Component in Post-COVID Pain Symptoms in Previously Hospitalized COVID-19 Survivors
Table 1
Baseline outcomes (mean ± SD) of the sample.
Variable
Total sample (n = 77)
S-LANSS ≥ 12 points (n = 19)
S-LANSS < 12 points (n = 58)
Demographic variables
Age (years)
60.0 ± 11.5
60.0 ± 8.0
60.2 ± 12.5
Height (m)
1.69 ± 0.09
1.68 ± 0.09
1.69 ± 0.09
Weight (kg)
75.8 ± 15.4
72.6 ± 12.7
74.8 ± 16.1
Pain and sensitization-related variables
Time with symptoms (months)
6.0 ± 0.8
5.6 ± 0.7
6.0 ± 0.9
Pain intensity (0–10)
5.4 ± 1.8
5.8 ± 1.8
5.3 ± 1.7
S-LANSS (0–24)
7.7 ± 6.5
15.6 ± 2.8
4.2 ± 4.1
Psychological variables
HADS-A (0–21)
5.8 ± 4.4
7.2 ± 4.1
5.3 ± 4.4
HADS-D (0–21)
5.7 ± 4.7
6.5 ± 4.4
5.4 ± 4.8
Cognitive and health-related variables
PSC (0–52)
16.1 ± 13.1
23.2 ± 11.5
14.0 ± 12.9
TSK-11 (0–44)
24.2 ± 9.1
27.5 ± 10.1
23.2 ± 8.5
HADS, hospital anxiety and depression scale; PSQI, Pittsburgh Sleep Quality Index; PCS, Pain Catastrophizing Scale; TSK-11: Tampa Scale for Kinesiophobia. Significant differences between individuals according to the CSI score (Student’s t-test, < 0.01).
